Chroneme interprets the trajectory before there is a reason to look. Every signal, from every provider, across years. No black box, by design. Intelligence clinicians can question, understand, and trust.
We tested Chroneme on data from 208 hospitals, across 49,850 ICU stays. It detected deterioration more than 35 hours before standard scoring systems flagged anything. When the same engine moved to an independent database, 99.4% of performance was retained.
Zohaib Akhtar is the founder of Chroneme. His cross-disciplinary background spans medicine, public health, biomedical design, business, and AI systems. Also founder of OpenCura. 13 patent families filed.
Chenyu Li, Co-Founder. Adam Wolfe, Co-Founder.
Founded 2025. Chroneme, Inc. 13 patent families filed. Contact: mail@chroneme.com
Chroneme has been validated across hundreds of thousands of ICU stays from 208 hospitals using the eICU Collaborative Research Database and MIMIC-IV. It detected clinical deterioration hours to days before standard ICU early warning systems flagged anything.
AUROC 0.926 for Chroneme versus 0.849 for the best general-purpose AI (Claude Sonnet 4.6). Same data, same conditions. Deterministic clinical decision support outperforming black-box AI.
Lead time: median 35 hours before standard scoring systems. Validated across multiple patient populations, age groups, and ICU types.